- Home
- APPS vs SEPN Comparison
APPS vs SEPN Comparison
Compare APPS & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- SEPN
- Stock Information
- Founded
- APPS N/A
- SEPN 2022
- Country
- APPS United States
- SEPN United States
- Employees
- APPS N/A
- SEPN N/A
- Industry
- APPS Multi-Sector Companies
- SEPN
- Sector
- APPS Miscellaneous
- SEPN
- Exchange
- APPS Nasdaq
- SEPN NYSE
- Market Cap
- APPS 562.7M
- SEPN 522.7M
- IPO Year
- APPS N/A
- SEPN 2024
- Fundamental
- Price
- APPS $5.46
- SEPN $13.88
- Analyst Decision
- APPS Hold
- SEPN Strong Buy
- Analyst Count
- APPS 3
- SEPN 5
- Target Price
- APPS $3.33
- SEPN $26.75
- AVG Volume (30 Days)
- APPS 4.5M
- SEPN 312.6K
- Earning Date
- APPS 08-05-2025
- SEPN 08-15-2025
- Dividend Yield
- APPS N/A
- SEPN N/A
- EPS Growth
- APPS N/A
- SEPN N/A
- EPS
- APPS N/A
- SEPN N/A
- Revenue
- APPS $490,506,000.00
- SEPN $977,000.00
- Revenue This Year
- APPS $8.47
- SEPN $3,429.67
- Revenue Next Year
- APPS $8.74
- SEPN N/A
- P/E Ratio
- APPS N/A
- SEPN N/A
- Revenue Growth
- APPS N/A
- SEPN 108.76
- 52 Week Low
- APPS $1.18
- SEPN $4.17
- 52 Week High
- APPS $7.77
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- APPS 51.89
- SEPN N/A
- Support Level
- APPS $4.88
- SEPN N/A
- Resistance Level
- APPS $5.68
- SEPN N/A
- Average True Range (ATR)
- APPS 0.35
- SEPN 0.00
- MACD
- APPS -0.04
- SEPN 0.00
- Stochastic Oscillator
- APPS 53.21
- SEPN 0.00
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.